Improvements in Skin Clearance and Patient-Reported Outcomes were Greater with Guselkumab Compared with Ustekinumab Among Patients with Persistent Mild Psoriasis After 16-Weeks of Treatment with Ustekinumab

Background: Introduction: Managing clinical symptoms is key to patients achieving freedom from plaque-psoriasis.1 For patients whose symptoms are not adequately controlled, switching to another therapy with a different mechanism-of-action may be warranted. In the Phase-3 NAVIGATE trial,2 patients with moderate-to-severe psoriasis were initially treated with ustekinumab (anti-interleukin- 12/23p40-subunit antibody). Patients with inadequate response to ustekinumab (IGA2:2) were randomized to either switch to guselkumab (anti-interleukin-23p19-subunit antibody) or continue ustekinumab. This post-hoc analysis evaluated the subgroup of patients with residual psoriasis of mild severity (IGA=2) after initial ustekinumab treatment.